Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

XENSE is an early-stage, private AI/ML diagnostics company targeting the neurology and psychiatry markets with its uTomo platform for advanced X-ray imaging. The company is in a pre-revenue, pre-clinical development stage and is currently raising capital from accredited investors via platforms like Wefunder and StartEngine. Leadership includes founder Ying Zhao as CEO/CTO and Dr. Sean Lavine heading Medical Affairs, indicating a blend of technical and clinical expertise. The primary near-term goals appear to be technology development, validation, and securing initial funding.

NeurologicalPsychiatric

Technology Platform

uTomo platform for next-generation X-ray imaging and AI, described as 'Meta CT,' aiming to generate advanced diagnostic data and digital biomarkers from X-ray sources.

Opportunities

The high unmet need for objective, scalable diagnostic tools in psychiatry and neurology presents a massive market opportunity.
A successful AI-based platform using low-cost X-ray infrastructure could enable widespread screening and monitoring, potentially integrating into standard care pathways with a subscription model.

Risk Factors

Major risks include the unproven technical feasibility of deriving meaningful neurological biomarkers from X-rays, significant regulatory hurdles for diagnostic AI, and reliance on crowdfunding which may not provide sufficient capital for the long development cycle required.

Competitive Landscape

The AI-medical imaging field is intensely competitive, with numerous companies developing algorithms for radiology. XENSE must differentiate its focus on neurology/psychiatry from X-ray data and demonstrate clear clinical utility against established imaging modalities like MRI and CT, as well as other digital biomarker approaches.